EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database

I Caruso, L Di Gioia, S Di Molfetta, M Caporusso, A Cignarelli, G P Sorice, L Laviola, F Giorgino

Journal of Endocrinological Investigation · 14.08.2024 · 47 (11) · 2671-2678

DOI: 10.1007/s40618-024-02441-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Endocrinological Investigation, online erschienen am 14.08.2024. Verfasst von I Caruso und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Uni…. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, United States Food and Drug Administration, Pharmacovigilance, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Recovery and Resilience Plan, Investment PE8 – Project Age-It: “Ageing Well in an Ageing Society”., Università degli Studi di Bari Aldo Moro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Randomized controlled trials with tirzepatide (TZP) displayed unprecedented glucose and body weight lowering efficacy in individuals with type 2 diabetes and/or obesity and a safety profile similar to that of glucagon-like peptide-1 receptor agonists (GLP-1RA), mainly characterized by gastrointestinal (GI) adverse events (AE). Concerns on diabetic retinopathy, pancreato-biliary disorders, and medullary thyroid cancer were also addressed. We aimed to investigate whether the same safety issues emerged from the FDA Adverse Event Reporting System (FAERS) post-marketing surveillance database.

Methods

OpenVigil 2.1-MedDRA-v24 and AERS Mine (data 2004Q1-2023Q3) were used to query the FAERS database. Reports of GI AE, diabetic retinopathy, pancreato-biliary disorders, and medullary thyroid cancer were investigated. The analysis was then filtered for age, gender, and designation as primary suspect. AE occurrence with TZP was compared to insulin, sodium-glucose cotransporter-2 inhibitors, metformin, and GLP-1RA.

Results

Disproportionate reporting of GI [i.e., nausea (ROR 4.01, 95% CI 3.85–4.19)] and pancreato-biliary disorders [i.e., pancreatitis (ROR 3.63, 95% CI 3.15–4.19)], diabetic retinopathy (ROR 4.14, 95% CI 2.34–7.30), and medullary thyroid cancer (ROR 13.67, 95% CI 4.35–42.96) was detected. TZP exhibited a similar risk of GI AE and medullary thyroid cancer and a lower risk of most pancreato-biliary AE and diabetic retinopathy vs. GLP-1RA.

Conclusions

TZP was associated with an increased risk of specific AE. However, its safety profile was similar to that of GLP-1RA, without increased risk of pancreato-biliary AE, diabetic retinopathy, and medullary thyroid cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adverse Drug Reaction Reporting SystemsUnited States Food and Drug AdministrationPharmacovigilanceDiabetes Mellitus, Type 2HumansUnited StatesMaleFemaleMiddle AgedDatabases, FactualHypoglycemic AgentsAgedAdultDrug-Related Side Effects and Adverse ReactionsThyroid NeoplasmsCarcinoma, Neuroendocrine

Stichwörter der Autor:innen

Adverse eventsGIPTirzepatideType 2 diabetes

Substanzen

Hypoglycemic Agents

Autor:innen und Institutionen

  • Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
  • Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy. francesco.giorgino@uniba.it.

Förderung

  • National Recovery and Resilience Plan, Investment PE8 – Project Age-It: “Ageing Well in an Ageing Society”.
  • Università degli Studi di Bari Aldo Moro

Zitieren

APA

Caruso, I., Di Gioia, L., Di Molfetta, S., Caporusso, M., Cignarelli, A., Sorice, G. P., Laviola, L., & Giorgino, F. (2024). The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Journal of Endocrinological Investigation, 47(11), 2671-2678. https://doi.org/10.1007/s40618-024-02441-z

Vancouver

Caruso I, Di Gioia L, Di Molfetta S, Caporusso M, Cignarelli A, Sorice GP, et al. The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Journal of Endocrinological Investigation. 2024;47(11):2671-2678. doi:10.1007/s40618-024-02441-z

BibTeX
@article{Caruso2024,
  author = {Caruso, I and Di Gioia, L and Di Molfetta, S and Caporusso, M and Cignarelli, A and Sorice, G P and Laviola, L and Giorgino, F},
  title = {The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database},
  journal = {Journal of Endocrinological Investigation},
  year = {2024},
  volume = {47},
  number = {11},
  pages = {2671--2678},
  doi = {10.1007/s40618-024-02441-z}
}
Kostenlos starten →